Matches in SemOpenAlex for { <https://semopenalex.org/work/W634237265> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W634237265 endingPage "11513" @default.
- W634237265 startingPage "11513" @default.
- W634237265 abstract "11513 Background: Several trials have consistently reported that there is marked heterogeneity in the magnitude of chemotherapy benefit according to the level of hormone receptor expression. Methods: We reviewed the medical records of early breast cancer patients with known receptor status who had anthracycline based adjuvant (CA, CE, CEF or CAF) CT between 1999–2006 in our institution. We recorded the clinical/pathologic characteristics of ER/PR+/+ and ER/PR−/− tumors (tms), analyzed survival outcome according to receptor status. Results: 258 of 318 tumors were both ER,PR positive. In the receptor positive (RP) subset % 40 patients were postmenopausal, %57 had nod positive disease, % 27 had breast conserving surgery (BCS). Her-2 was 2+/3+ in % 12 tms and %67/20 tms were grade 2/3 respectively. In the receptor negative (RN) subset (n:60) all patients were postmenopausal, %48 had nod positive disease, % 24 had BCS. Her-2 was 2+/3+ in % 24 tumors, %60 were triple negative and %41 /55 pts had grade 2/3 tumors respectively. 8-year overall survivals were %88 and %89 in the RP and RN subsets respectively and the curves did not diverge over time. 3-year and 8-year DFS were %88 and %64 in the RP group. 3-year and 8-year DFS were %81 and %66 in the RN group. The DFS curves converge at fourth year and then slightly diverge. Conclusions: Patients with ER/PR positive tms had fewer relapses than those with RN tms in the first four years following anthracycline based chemotherapy. Thereafter the difference in relapse patterns between RP and RN groups disappear. More effective, possibly targeted, treatment strategies are needed for RN tms and optimization of endocrine therapy is crucial in RP group. No significant financial relationships to disclose." @default.
- W634237265 created "2016-06-24" @default.
- W634237265 creator A5018888045 @default.
- W634237265 creator A5024399705 @default.
- W634237265 creator A5033738148 @default.
- W634237265 creator A5058779660 @default.
- W634237265 creator A5064011743 @default.
- W634237265 creator A5076620707 @default.
- W634237265 creator A5078640497 @default.
- W634237265 creator A5082587759 @default.
- W634237265 date "2008-05-20" @default.
- W634237265 modified "2023-10-10" @default.
- W634237265 title "Benefit from adjuvant anthracyclines according to hormone receptor status" @default.
- W634237265 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.11513" @default.
- W634237265 hasPublicationYear "2008" @default.
- W634237265 type Work @default.
- W634237265 sameAs 634237265 @default.
- W634237265 citedByCount "0" @default.
- W634237265 crossrefType "journal-article" @default.
- W634237265 hasAuthorship W634237265A5018888045 @default.
- W634237265 hasAuthorship W634237265A5024399705 @default.
- W634237265 hasAuthorship W634237265A5033738148 @default.
- W634237265 hasAuthorship W634237265A5058779660 @default.
- W634237265 hasAuthorship W634237265A5064011743 @default.
- W634237265 hasAuthorship W634237265A5076620707 @default.
- W634237265 hasAuthorship W634237265A5078640497 @default.
- W634237265 hasAuthorship W634237265A5082587759 @default.
- W634237265 hasConcept C121608353 @default.
- W634237265 hasConcept C126322002 @default.
- W634237265 hasConcept C143998085 @default.
- W634237265 hasConcept C23589133 @default.
- W634237265 hasConcept C2776694085 @default.
- W634237265 hasConcept C2776802502 @default.
- W634237265 hasConcept C2777757722 @default.
- W634237265 hasConcept C2777863537 @default.
- W634237265 hasConcept C2781467025 @default.
- W634237265 hasConcept C29456083 @default.
- W634237265 hasConcept C530470458 @default.
- W634237265 hasConcept C71924100 @default.
- W634237265 hasConcept C90924648 @default.
- W634237265 hasConceptScore W634237265C121608353 @default.
- W634237265 hasConceptScore W634237265C126322002 @default.
- W634237265 hasConceptScore W634237265C143998085 @default.
- W634237265 hasConceptScore W634237265C23589133 @default.
- W634237265 hasConceptScore W634237265C2776694085 @default.
- W634237265 hasConceptScore W634237265C2776802502 @default.
- W634237265 hasConceptScore W634237265C2777757722 @default.
- W634237265 hasConceptScore W634237265C2777863537 @default.
- W634237265 hasConceptScore W634237265C2781467025 @default.
- W634237265 hasConceptScore W634237265C29456083 @default.
- W634237265 hasConceptScore W634237265C530470458 @default.
- W634237265 hasConceptScore W634237265C71924100 @default.
- W634237265 hasConceptScore W634237265C90924648 @default.
- W634237265 hasIssue "15_suppl" @default.
- W634237265 hasLocation W6342372651 @default.
- W634237265 hasOpenAccess W634237265 @default.
- W634237265 hasPrimaryLocation W6342372651 @default.
- W634237265 hasRelatedWork W1255356622 @default.
- W634237265 hasRelatedWork W1991307975 @default.
- W634237265 hasRelatedWork W2370076106 @default.
- W634237265 hasRelatedWork W2381572134 @default.
- W634237265 hasRelatedWork W2791179561 @default.
- W634237265 hasRelatedWork W2969515167 @default.
- W634237265 hasRelatedWork W3030794620 @default.
- W634237265 hasRelatedWork W4212973790 @default.
- W634237265 hasRelatedWork W4292566224 @default.
- W634237265 hasRelatedWork W4322770243 @default.
- W634237265 hasVolume "26" @default.
- W634237265 isParatext "false" @default.
- W634237265 isRetracted "false" @default.
- W634237265 magId "634237265" @default.
- W634237265 workType "article" @default.